Skip to main content

Table 2 Genotype and haplotype frequencies of VEGF 3′-UTR polymorphisms

From: Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans

  Without MetS With MetS
Genotype/Haplotype Control (n = 305) CC (n = 166) RC (n = 113) Control (n = 95) CC (n = 98) RC (n = 73)
VEGF 1451CC 209 (68.5) 108 (65.1) 64 (56.6) 65 (68.4) 72 (73.5) 45 (61.6)
VEGF 1451CT 81 (26.6) 50 (30.1) 43 (38.1) 29 (30.5) 23 (23.5) 27 (37.0)
VEGF 1451TT 15 (4.9) 8 (4.8) 6 (5.3) 1 (1.1) 3 (3.1) 1 (1.4)
HWE-p 0.059 0.483 0.724 0.251 0.493 0.167
VEGF 1612GG 213 (69.8) 127 (76.5) 87 (77.0) 67 (70.5) 68 (69.4) 54 (74.0)
VEGF 1612GA 83 (27.2) 36 (21.7) 21 (18.6) 27 (28.4) 29 (29.6) 18 (24.7)
VEGF 1612AA 9 (3.0) 3 (1.8) 5 (4.4) 1 (1.1) 1 (1.0) 1 (1.4)
HWE-p 0.791 0.809 0.022 0.336 0.271 0.714
VEGF 1725GG 278 (91.1) 147 (88.6) 96 (85.0) 81 (85.3) 79 (80.6) 61 (83.6)
VEGF 1725GA 27 (8.9) 19 (11.4) 17 (15.0) 14 (14.7) 19 (19.4) 12 (16.4)
VEGF 1725AA 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
HWE-p 0.419 0.434 0.387 0.438 0.288 0.444
VEGF 1451C/1612G/1725G 398 (65.2) 221 (65.6) 140 (61.9) 130 (68.4) 134 (68.4) 96 (65.8)
VEGF 1451T/1612G/1725G 111 (18.2) 66 (19.9) 55 (24.3) 31 (16.3) 29 (14.8) 29 (19.9)
VEGF 1451C/1612A/1725G 74 (12.1) 26 (7.8) 14 (6.2) 15 (7.9) 14 (7.1) 9 (6.2)
VEGF 1451C/1612A/1725A 27 (4.4) 16 (4.8) 17 (7.5) 14 (7.4) 17 (8.7) 11 (7.5)
VEGF 1451C/1612G/1725A 0 (0.0) 3 (0.9) 0 (0.0) 0 (0.0) 2 (1.0) 1 (0.7)
  1. Vascular endothelial growth factor (VEGF), Colon cancer (CC), Rectal cancer (RC), Metabolic syndrome (MetS), Hardy-Weinberg equilibrium (HWE).